MetaVia Inc.

MetaVia Inc. is a clinical-stage biotechnology company developing novel pharmaceuticals for cardiometabolic diseases. Its current pipeline is focused on two programs targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity, with R&D spending centered on advancing those product candidates through clinical development.

1.93

1.93

— MetaVia Inc.
%
Lead clinical programs0% Core pipeline assets under development for MASH and obesity, including Vanoglipel (DA-1241) and DA-1726.
Research and development services100% Internal and outsourced R&D activities such as CRO work, consultants, and clinical operations.
Manufacturing and supply chain support0% Drug product manufacturing, storage, and CMO-related services used for preclinical and clinical studies.
Licensing and collaboration arrangements0% Third-party licensing and shared-services arrangements that support development programs.

MetaVia does not sell commercial medicines yet; its primary stakeholders are clinical investigators, CROs, CMOs, and...

  • Clinical development vendorsprimary

    CROs, consultants, and trial operators that execute studies and provide development expertise.

  • Manufacturing partnersprimary

    CMOs and related suppliers that make and store drug product for preclinical and clinical use.

  • Licensing and collaboration partnerssecondary

    Third parties such as Dong-A ST that provide shared services, rights, or funding support.

  • Future prescribers and patientsemerging

    Physicians and patients in MASH and obesity markets who would use approved therapies if development succeeds.

MetaVia is a U.S.-based company and reports under U.S. GAAP, with operations centered on development activities rather...

  • •Headquartered in the United States
  • •No country-level revenue disclosure in the excerpts
  • •R&D and clinical work likely coordinated through U.S. operations
  • •Third-party development and manufacturing may be global
  • •Geographic exposure is mainly regulatory and trial-site related

MetaVia's near-term strategy is to conserve capital while advancing its MASH and obesity programs through clinical...

01
Advance the MASH and obesity pipelineshort-term

Clinical progress is the main driver of future value and partnering optionality.

02
Secure additional financingshort-term

The company expects current cash to fund operations only into 2026 and may need more capital to continue trials.

03
Manage development spend and runwaymedium-term

R&D is the primary cash use, so disciplined spending determines how long the pipeline can progress.

MetaVia faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory setbacks, and...

critical

Clinical development failure

Pipeline value depends on successful outcomes for Vanoglipel and DA-1726.

Scope
MASH and obesity programs
Materiality
high
high

Going-concern and liquidity risk

The company states it expects cash to fund operations only into 2026 and may need additional capital.

Scope
Clinical trials and corporate operations
Materiality
high
high

Dilution from equity financing

Operations have been funded primarily through equity offerings and convertible securities.

Scope
Existing shareholders
Materiality
high
medium

Regulatory and trial execution risk

Clinical-stage companies depend on approvals, site execution, and compliance with regulatory requirements.

Scope
CROs, CMOs, and trial operations
Materiality
medium
Warrant liability fair value
Other income/expense
Stock-based compensation
Operating expenses and net loss
Accrued expenses
Operating liabilities and expense timing
R&D expense recognition
Reported operating loss

Editas Medicine, Inc.

EDIT · Biological Products, (No Diagnostic Substances)

VitaNova Life Sciences Corp

VNOV · Wholesale-Apparel, Piece Goods & Notions

vTv Therapeutics Inc.

VTVT · Pharmaceutical Preparations

Viking Therapeutics, Inc.

VKTX · Pharmaceutical Preparations

Ventyx Biosciences, Inc.

Pharmaceutical Preparations

Sagimet Biosciences Inc.

SGMT · Pharmaceutical Preparations

: 28/04/2026